CL2020000855A1 - Anticuerpos monoclonales anti-trkb y métodos de uso. - Google Patents

Anticuerpos monoclonales anti-trkb y métodos de uso.

Info

Publication number
CL2020000855A1
CL2020000855A1 CL2020000855A CL2020000855A CL2020000855A1 CL 2020000855 A1 CL2020000855 A1 CL 2020000855A1 CL 2020000855 A CL2020000855 A CL 2020000855A CL 2020000855 A CL2020000855 A CL 2020000855A CL 2020000855 A1 CL2020000855 A1 CL 2020000855A1
Authority
CL
Chile
Prior art keywords
antibodies
methods
trkb
agonist
monoclonal anti
Prior art date
Application number
CL2020000855A
Other languages
English (en)
Spanish (es)
Inventor
Susan D Croll
Min Gao
Ying Hu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2020000855A1 publication Critical patent/CL2020000855A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CL2020000855A 2017-11-30 2020-03-31 Anticuerpos monoclonales anti-trkb y métodos de uso. CL2020000855A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762592657P 2017-11-30 2017-11-30

Publications (1)

Publication Number Publication Date
CL2020000855A1 true CL2020000855A1 (es) 2020-07-31

Family

ID=64665125

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2020000855A CL2020000855A1 (es) 2017-11-30 2020-03-31 Anticuerpos monoclonales anti-trkb y métodos de uso.
CL2024002612A CL2024002612A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.
CL2024002614A CL2024002614A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2024002612A CL2024002612A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.
CL2024002614A CL2024002614A1 (es) 2017-11-30 2024-08-30 Anticuerpo anti-receptor tropomiosina quinasa b (trkb); composición farmacéutica; y su uso.

Country Status (18)

Country Link
US (3) US11066474B2 (https=)
EP (1) EP3717514A1 (https=)
JP (2) JP7438937B2 (https=)
KR (1) KR20200090779A (https=)
CN (2) CN111372949B (https=)
AU (3) AU2018375340B2 (https=)
BR (1) BR112020006976A2 (https=)
CA (1) CA3083452A1 (https=)
CL (3) CL2020000855A1 (https=)
CO (1) CO2020004075A2 (https=)
EA (1) EA202090966A1 (https=)
IL (1) IL273538B2 (https=)
MA (1) MA51207A (https=)
MX (3) MX2020003550A (https=)
MY (1) MY203247A (https=)
PH (1) PH12020550409A1 (https=)
SG (1) SG11202002665UA (https=)
WO (1) WO2019108662A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use
IL310006A (en) * 2017-11-30 2024-03-01 Regeneron Pharma Non-human animals containing a humanized TRKB locus
JP7524158B2 (ja) * 2019-03-04 2024-07-29 公益財団法人東京都医学総合研究所 Ｔｒｋ断片をコードする核酸構築物、及びその利用
US12559560B2 (en) * 2020-01-30 2026-02-24 Fred Hutchinson Cancer Center Antibody-based compositions for targeting tropomyosin receptor kinase B (TrkB) isoforms
WO2023125485A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkB ANTIBODY AND APPLICATION THEREOF
TW202342494A (zh) 2022-03-30 2023-11-01 日商肽夢想股份有限公司 具有TrkB結合活性之肽複合物
CN120665203B (zh) * 2025-06-18 2026-03-27 广东优赛生物医药科技有限公司 一种药物组合物及其在治疗中枢性肥胖中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US6225282B1 (en) 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2006133164A2 (en) 2005-06-06 2006-12-14 Wyeth Anti-trkb monoclonal antibodies and uses thereof
EP1988923A1 (en) * 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating unwanted weight loss or eating disorders by administering a trkb agonist
EP1988920A1 (en) 2006-02-02 2008-11-12 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
WO2008058127A2 (en) 2006-11-09 2008-05-15 Irm Llc Agonist trkb antibodies and uses thereof
CA2672750A1 (en) * 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Trkb agonists for treating autoimmune disorders
WO2009048605A1 (en) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists
CA2712298C (en) 2008-01-17 2015-11-24 Irm Llc Improved anti-trkb antibodies
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
WO2011103667A1 (en) 2010-02-26 2011-09-01 6452728 Canada Inc. Agonistic antibodies to trkb receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
US10080745B2 (en) 2013-11-25 2018-09-25 The Regents Of The University Of California Santa Cruz Piericidin bacterial inhibitors
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
CA2993645A1 (en) 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
CA3005491A1 (en) 2015-11-17 2017-05-26 Glaxosmithkline Intellectual Property Development Limited Binding agonists for treatment of neurological and other disorders
JP2019517787A (ja) * 2016-05-03 2019-06-27 ザ スクリプス リサーチ インスティテュート 神経変性障害の処置のためのＴｒｋＢアゴニスト抗体
US9914781B1 (en) 2016-11-08 2018-03-13 Glaxosmithkline Intellectual Property Development Limited Binding agonist for treatment of neurological and other disorders
EP4095161A1 (en) * 2017-03-15 2022-11-30 Tsinghua University Novel anti-trkb antibodies
WO2019108662A1 (en) * 2017-11-30 2019-06-06 Regeneron Pharmaceuticals, Inc. Anti-trkb monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
BR112020006976A2 (pt) 2020-10-13
CL2024002614A1 (es) 2025-01-24
AU2026200583A1 (en) 2026-02-19
MX2025001445A (es) 2025-03-07
EP3717514A1 (en) 2020-10-07
JP7438937B2 (ja) 2024-02-27
JP2024016204A (ja) 2024-02-06
US20240309100A1 (en) 2024-09-19
CN121181700A (zh) 2025-12-23
KR20200090779A (ko) 2020-07-29
IL273538B2 (en) 2024-10-01
US20220411515A1 (en) 2022-12-29
JP2021507677A (ja) 2021-02-25
US12037401B2 (en) 2024-07-16
IL273538B1 (en) 2024-06-01
SG11202002665UA (en) 2020-04-29
AU2018375340A1 (en) 2020-05-07
EA202090966A1 (ru) 2020-08-26
MA51207A (fr) 2020-10-07
CA3083452A1 (en) 2019-06-06
AU2018375340B2 (en) 2025-10-30
IL273538A (en) 2020-05-31
NZ763618A (en) 2025-05-02
AU2026200616A1 (en) 2026-02-19
MX2025001444A (es) 2025-03-07
WO2019108662A1 (en) 2019-06-06
CN111372949B (zh) 2026-02-03
MX2020003550A (es) 2020-08-03
MY203247A (en) 2024-06-19
CO2020004075A2 (es) 2020-08-31
CN111372949A (zh) 2020-07-03
US20190161551A1 (en) 2019-05-30
PH12020550409A1 (en) 2021-04-12
US11066474B2 (en) 2021-07-20
CL2024002612A1 (es) 2025-01-24

Similar Documents

Publication Publication Date Title
CL2020000855A1 (es) Anticuerpos monoclonales anti-trkb y métodos de uso.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CL2018000703A1 (es) Anticuerpos anti-pdgfr-beta y usos de los mismos (divisional de sol. n°1924-15)
CO2019012998A2 (es) Proteínas de unión a antígenos trem2 y usos de estas
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
MX374501B (es) Formulaciones de anticuerpos de her2 subcutáneas.
IL282624A (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2021003765A (es) Proteínas il-12 de fusión a fc heterodimérico.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
CL2018000101A1 (es) Anticuerpos dirigidos contra il-33 y sus usos (divisional de la solicitud 201502469)
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
GT201800018A (es) Anticuerpo anti-cd154 con características de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
EA201791005A1 (ru) Улучшенные антитела против il-6
MX393900B (es) Uso de gaboxadol en el tratamiento de tinnitus.
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
AR115790A1 (es) Apirasas solubilizadas, métodos y usos
CO6592047A2 (es) Formulación tópica oftálmica de péptidos
MX2018016003A (es) Tratamiento combinado para lesiones neurológicas.
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.
MX2018002298A (es) Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.